The pharmaceutical industry faces an innovation crisis with declining R&D productivity, rising costs, and regulatory challenges impacting drug development.

The global peptide and anticoagulant drugs market is witnessing significant growth, driven by factors such as the rising prevalence of cardiovascular diseases, technological advancements, and the ...

Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) ('Ligand”) announced today the pricing of $400.0 million aggregate ...

Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) ('Ligand”) announced today its intention to offer $400.0 million aggregate principal amount of convertible senior notes due 2030 (the 'notes”) in a ...

Serina Therapeutics, Inc. ("Serina") (NYSE American: SER), a clinical-stage biotechnology company advancing its lead IND candidate, SER-252, for advanced ...

Since April 2, or “Liberation Day,” as the White House now calls it, Donald Trump has invoked emergency legal powers to ...

The drug price negotiation program has withstood another procedural effort in striking down one of the Inflation Reduction Act’s most significant provisions. | A federal court of appeals judge upheld ...

Lilly has been chasing—and gaining on—its chief metabolic medicine rival Novo Nordisk and its counterpart GLP-1s Ozempic and ...

Following a barrage of letters from President Donald Trump urging 17 large pharmaceutical companies to implement Most Favored ...

The Trump administration has been talking to drugmakers about ways to raise prices of medicines in Europe and elsewhere to ...

Three federal courts reject legal challenges to Medicare drug price negotiation Judges side with government in cases filed by ...

Germany's CureVac and Britain's GSK have settled a years-long patent dispute with Pfizer and its partner BioNTech over the ...